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Abstract: Microbial infections are a major public health concern. Antimicrobial peptides (AMPs)
have been demonstrated to be a plausible alternative to the current arsenal of drugs that has become
inefficient due to multidrug resistance. Herein we describe a new AMP family, namely the super-
cationic peptide dendrimers (SCPDs). Although all members of the series exert some antibacterial
activity, we propose that special attention should be given to (KLK)2KLLKLL-NH2 (G1KLK-L2KL2),
which shows selectivity for Gram-negative bacteria and virtually no cytotoxicity in HepG2 and
HEK293. These results reinforce the validity of the SCPD family as a valuable class of AMP and
support G1KLK-L2KL2 as a strong lead candidate for the future development of an antibacterial
agent against Gram-negative bacteria.
Keywords: solid-phase peptide synthesis; antimicrobial peptides; Gram-positive; Gram-negative;
therapeutic index
1. Introduction
The emergence and spread of multidrug-resistant (MDR) bacteria have become a
major challenge for antimicrobial therapy [1]. Indeed, multidrug resistance is a major
public health issue [2]. The scenario has become increasingly more alarming given the large
gap between the development of novel antibiotics and the burden of infections due to MDR
bacteria [3]. Thus, research into new antimicrobial products and strategies is urgent [4].
Antimicrobial peptides (AMPs), either natural products produced by microorganisms,
animals, plants and bacteria, or synthetic ones, are one of the main options to overcome
bacterial drug resistance [5]. In principle, this is based on the fact that they are potent
antimicrobials and they do not share mechanisms of action with known traditional antibi-
otics. Moreover, some peptides, particularly those similar to animal defense AMPs, have
immunomodulatory properties [6]. Widespread resistance, including extremely resistant
microorganisms, together with the lack of new antimicrobial agents, has led to the revival
of abandoned antimicrobials, such as colistin, a natural AMP, and has driven research
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into the synthesis of similar molecules [7], as well as the search for new ones [8,9]. In
general, AMPs have a positive net charge that allows them to interact selectively with
bacterial membranes and also with other negatively charged structures, including DNA,
lipopolysaccharide (LPS) and lipoteichoic acids (LTAs). Although membrane permeabiliza-
tion seems to be the main mechanism of action of AMPs, a few additional mechanisms have
also been reported, such as inhibition of the biosynthesis of macromolecules, inhibition
of nucleic acid synthesis and alterations in intracellular translocation and in metabolism.
Transcriptomics studies have revealed that AMPs commonly lead to a dramatic alteration
of bacterial gene expression. Surprisingly, the toxicity of AMPs on eukaryotic cells in vitro
is generally low.
Numerous AMPs, including linear alpha helical amphipathic peptides [10] and
also peptidomimetics such as peptoids [11], foldamers [12] and other amide-containing
oligomers [13], act by disrupting microbial membranes. Peptides based on a dendrimer
structure are an interesting case and could be considered multiple ramified peptides
through a branched unit, which is usually a Lys residue. This concept has been explored
by Reymond et al. using mostly units based on Leu-Lys [14–16]. In the study herein,
we examined the antimicrobial activity of different generations of super-cationic peptide
dendrimers based on the triad XLX, where X are residues of Lys, Orn or Arg.
2. Results and Discussion
2.1. Design and Synthesis of Super-Cationic Peptide Dendrimers (SCPDs)
Molecule design was based on the following three main physical driving forces behind
the antibacterial activity of cationic AMPs: (i) highly positive charge to enhance interaction
with the anionic lipids of the cell wall in bacteria, (ii) hydrophobic content to facilitate
membrane insertion and (iii) flexibility to allow conformational changes when interacting
with membranes [17,18]. With this in mind, two “mirror sequences” were used: LLKLL
for G0, which has a high hydrophobic content, and XLX for the branches of the following
generations, where X is a basic residue, and hence this sequence contributes two positive
charges to each branch. The branching is afforded by the incorporation of a Lys residue,
which, after reaction on the α- and ε- amino groups, can be considered as contributing
to the hydrophobicity of the molecule. Moreover, we included a series of compounds
with N-terminals acylated with different lengths of the acylating moiety (acetyl, hexyl and
dodecyl), which directly affects the hydrophobicity of the resulting molecule (Table 1).
Table 1. SPCDs and their charges.
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Table 1. Cont.













In blue are the basic residues, positively charged at physiological pH. a The acyl moieties have been considered as hydrophobic residues.
All the constructs were synthesized by standard solid-phase peptide synthesis (SPPS)
following the Fmoc/tBu methodology. They were then purified to >95% homogeneity
by reverse-phase HPLC and characterized by LCMS. The schematic representation of the
10 compounds is given in Figure 1A, and a 2-D representation of G3KLK-L2KL2 is shown
in Figure 1B.
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2.2. Antimicrobial Action (MIC and MBC)
The antimicrobial activity of the 10 peptide dendrimers described before was first
assayed against a panel of antibiotic-susceptible reference bacterial strains (three Gram-
positive and two Gram-negative). The MIC (minimum inhibitory concentration) and MBC
(minimum bactericidal concentration) values ranged from 8 to 256 µg/mL, as can be seen
in Table 2.
It is acknowledged that there is a poor understanding of why the bacteria in vitro
susceptibility against an antibacterial agent results in pitfalls when tested in clinical in-
fections. The MIC determination only concerns two factors, bacteria and drug while in
clinical infection, but there is an extra factor to be considered: the patient. To simulate an
environment more realistic, the MICs are determined by adding 50% of human serum to
the testing media. In fact, MIC values, as well as time–kill studies, of some compounds
can present significant modifications in their antimicrobial capability when tested in the
presence of human serum. This is the case of Mu1140, a peptide produced by Lactococcus
lactis; its MIC increased up to fourfold when tested against S. pneumoniae in the presence of
human serum, likely because the antibiotic binding to serum proteins results in a lower
effective concentration. In contrast, the opposite outcome was seen against S. aureus—MIC
decreases to one-fourth [17]. In our study, the addition of 50% human serum had no effect
on MIC values in any of the bacterial strains tested.














MIC 50%HS * MBC MIC
50%
HS * MBC MIC
50%
HS * MBC MIC
50%
HS * MBC MIC
50%
HS MBC
G3KLK-L2KL2 16 16 16 4–8 8 8 64 64 64 32 32 32 16 16 16
G2KLK-L2KL2 32 32 32 8 8 8 32 64 32 16 32 32 8–16 16 16
Ac-G2KLK-L2KL2 64 64 128 8–16 16 16 64 128 128 8–16 16 16 8–16 16 16
Hx-G2KLK-L2KL2 128 256 128 64 64 128 32 32 64 64 64 64 64 64 64
Dd-G2KLK-L2KL2 >128 ND ND >128 ND ND >128 ND ND >128 ND ND >128 ND ND
G2RLR-L2RL2 32 32 32 16 32 16 16 32 16 64 64 64 64 64 64
G2OLO-L2OL2 32 32 32 32 32 32 8 16 8 32 32 32 32 32 32
G1KLK-L2KL2 128 >128 128 64 128 64 >128 ND ND 32 32 32 32 32 32
G1RLR-L2RL2 16 32 16 32 32 32 4 8 4 8 16 8 16 32 16
G1OLO-L2OL2 64 64 64 32 32 32 16 16 16 8 8 8 16 16 16
Meropenem 0.25 ND ND 0.062 ND ND <0.25 ND ND 0.125 ND ND 1 ND ND
* MIC values in the presence of 50% human serum.
The MIC values appear to indicate that the tested compounds are broad-spectrum
antimicrobials since they exerted activity against both Gram-positive and -negative strains.
Only compound G1KLK-L2KL2 showed a certain degree of selectivity against Gram-
negative strains. In spite of the fragility of the information provided by MIC values, a
comparison of the compounds indicated that (i) the different levels of branching does not
significantly affect antimicrobial activity against the bacterial strains tested, and (ii) the
acylation of the N-termini does not contribute to improving this activity. In contrast, a
longer acyl chain was revealed as being detrimental, giving higher MIC values. In this
regard, the peptide dendrimer Dd-G2KLK-L2KL2 was discarded for further experiments.
Comparison of the MBC and MIC values revealed that they were very close, in most
cases differing in one level of dilution, which is insignificant. This finding would suggest
that this family of peptide dendrimers exert bactericidal activity. To confirm this hypothesis,
time–kill kinetics and growth curve studies were conducted, and they are discussed in a
further section.
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Next, the antimicrobial action of the compounds was tested on resistant strains: MRSA
(methicillin-resistant S. aureus, Table 3), VRE (vancomycin-resistant Enterococcus, Table 4)
and CRE (carbapenem-resistant Enterobacteriaceae, Table 5). As expected, antimicrobial
activity against resistant isolates did not differ significantly from the values measured
in susceptible strains. This observation suggests that although bacterial resistance to
SCPDs cannot be ruled out, the mechanisms of such resistance would be different to those
determining resistance to conventional antibiotics.

















B11970 32 64 128 64 32 64 16 64 1 >512
P10781 16 64 128 64 64 64 32 64 1 >512
P10747 16 64 128 64 64 64 32 64 1 >512
S37938 32 64 128 64 32 64 32 64 1 >512
S18155 32 64 128 64 64 64 16 64 1 >512
B13178 32 64 128 64 32 64 16 64 1 >512
440260 32 64 128 64 32 64 16 64 1 >512
S18970 32 64 128 64 32 64 16 64 1 >512
P11520 16 64 128 64 32 64 16 64 1 512
T5683 32 64 128 64 64 64 16 64 1 >512

















951245262 16 64 64 128 16 32 64 16 >128
951234856 32 32 64 64 32 64 32 16 >128
951208931 16 32 128 64 16 32 32 32 >128
938636470 32 32 64 128 16 64 64 16 >128
938666613 16 32 128 64 16 32 32 32 >128
938600912 16 32 64 64 16 32 32 16 >128
938072607 32 32 128 64 32 64 32 32 >128
944414000 32 32 128 64 16 64 32 32 >128
945530665 32 32 128 64 16 32 32 32 >128
U43821 32 32 128 64 16 32 32 32 >128


















BM-12 >256 64 64 128 64 64 8 8 >32
NDM4-
FEK 256 32 64 64 32 32 8 8 >32
KPC L2l 32 32 64 64 64 32 8 8 16
OXA-48
501 16 32 32 128 64 16 16 16 2
IMP JAP 64 32 64 >256 64 8 8 8 8
As reflected by the MIC values, the SCPDs synthesized apparently work as broad-
spectrum antimicrobials since they show activity against both Gram-positive and -negative
bacterial strains. The observation that the MIC values are very close for the two types of
bacteria would suggest no differences in the mode of action exerted by the compounds.
Thus, this is an indication that permeability is not an obstacle for SCPD action. In principle,
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the outer membrane of Gram-negative bacteria is a permeability barrier and a first obstacle
preventing antimicrobials from exerting their action.
Furthermore, it is relevant to bear in mind that vancomycin is the last resort to
treat MRSA infections as it is nephrotoxic, inducing interstitial nephritis and tubular
cell damage. Furthermore, vancomycin resistance is spreading. In this context, there
is an urgent need to explore new, less toxic compounds with activity against MRSA as
alternatives to vancomycin. In this regard, SCPDs emerge as promising molecules since
they also covered vancomycin-resistant infections.
2.3. Cytotoxicity
To assess the toxicity of the synthesized peptide dendrimers on eukaryotic cells,
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used
in two cell lines: HepG2 (human liver cancer cell line) and HEK293 (line derived from
human embryonic kidney cells). The most branched peptide, G3KLK-L2KL2, showed the
highest toxicity, with an IC50 of 25.7 and 53.9 µg/mL for HepG2 and HEK293, respectively
(Figure 2). Compared with the MIC for this compound, these viability values make it
unsuitable as a therapeutic application. On the other hand, the least branched peptide
consisting of Lys as basic residues (G1KLK-L2KL2) did not show toxicity at the range of
concentrations tested.
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was exhibited by the compounds consisting of Arg as basic residues, especially in the case 
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Figure 2. Cytotoxicity of G3KLK-L2KL2, G3KLK-L2KL2 and G3KLK-L2KL2 in HepG2 and HEK293 cell lines.
The compounds included in the G2 group (G2KLK-L2KL2, G2RLR-L2RL2, G2OLO-
L2OL2) showed less toxicity than the G3 one. All the IC50 values for the G2 group were 3
to 4 times higher than the corresponding MIC. However, of note, the lower cell viability
was exhibited by the compounds consisting of Arg as basic residues, especially in the case
of HEK293 cells (Figure 3). The improvement of cell viability testing the G1 group, with
one less branching level, was significant. Moreover, a similar behavior was observed in
this group, the Arg-containing compounds once again being the most toxic.
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wells. Thus, it is reasonable that some differences in the concentrations to inhibit growth
may differ between both culture conditions. On the other hand, the time–kill curves have
been run at below MIC concentrations.
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In contrast, the curves for E.coli (Figure 5) showed that all the tested compounds killed
the bacteria in less than 1 h at MIC, 1/2 MIC and 1/4 MIC, and no regrowth was seen after
24 h (Figure S1, SI).
This devastating action of all four compounds even at 1/4 MIC prompted us to examine
the potential therapeutic index (TI) for each one, considering this concentration and toxicity
(IC50) in HepG2 and Hek293 cell lines. In this regard, we found that G2RLR-L2RL2 would
have a TI of approximately 6 and 4, respectively, which are not acceptable values for
therapeutic applications. Compound G2OLO-L2OL2 showed better results, with a TI of 70
and 100 for HepG2 and Hek293 cells, respectively. These values could allow this compound
to be studied further. Finally, the compounds G1KLK-L2KL2 and G1OLO-L2OL2 did not
show toxicity for the two cell lines. The TI could be determined only for G1OLO-L2OL2,
which had an index of 235 for the kidney cell line. On the basis of our results, G1KLK-L2KL2
and G1OLO-L2OL2 emerge as the best candidates as new antimicrobial agents against
E. coli.
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In another Gram-negative bacteria, P. aeruginosa (Figure 6), a bacterial species charac-
terized by intrinsic resistance to many antimicrobials, the action of the tested compounds
was less dramatic that in previous case. Nevertheless, at MIC and 1/2 MIC, compound
G2RLR-L2RL2 reduced the bacterial population to almost zero and no regrowth was appre-
ciated after 24 h. However, at 1/4 MIC, the bacterial population remained partially inhibited
at the beginning of the exposure. At the MIC, G2OLO-L2OL2 killed all bacteria within the
first hour of exposure and regrowth was observed after the second hour. A similar pattern
was seen when this compound was tested at 1/2 MIC and 1/4 MIC, although the bacterial
population was not totally eliminated in these cases. After the second hour onwards,
the bacterial population started to grow, but at a slower rate than in the control. This
observation may suggest that, at low concentrations, G2OLO-L2OL2 acts as a bacteriostatic
agent. A delay in antimicrobial action was also observed at 1/2 MIC in comparison with
1/4 MIC. This phenomenon has been referred to as a paradoxical effect (or Eagle effect) [18].
In the case of G1KLK-L2KL2, all bacteria were eliminated after the first hour of exposure
at the MIC and no regrowth was detected in the following 24 h. When 1/2 MIC was used,
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a reduction in bacteria of four orders of magnitude was observed after 1 h, but bacteria
showed regrowth later on. The bacteria showed the same behavior in response to 1/4 MIC,
but the reduction was only two magnitudes of order. Finally, G1OLO-L2OL2 had no effect
at any concentration tested.
Regarding the TIs, again as in the case of E. coli, G2RLR-L2RL2 gave small values and
were lower (<2) in the case of P. aeruginosa, meaning this compound will have very poor
therapeutic applicability. G2OLO-L2OL2 showed TI values (TI = 35 for HepG2 and TI = 50
for Hek293) that could be considered for therapeutic use, although the killing effect was
observed only for a limited time. G1KLK-L2KL2 is the compound of choice since it showed
the lowest cytotoxicity.
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2.5. Effects on Growth Kinetics
The two compounds based on Orn as basic residues, G2OLO-L2OL2 and G1OLO-
L2OL2, and G1KLK-L2KL2 as the most promising, were assayed for their effect on the
growth curve of the same bacterial strains used in the time–killing study. The effect of
these compounds on S. aureus was negligible (Figure 7, upper panel) at MIC, 1/2 MIC
and 1/4 MIC. This lack of effect confirmed the results of the time–kill kinetics experiments
shown above and are in disagreement with the values shown in MIC determinations. The
assay in E. coli revealed that the three compounds abolished bacterial growth (Figure 7,
central panel), irrespective of the concentration used (MIC, 1/2 MIC and 1/4 MIC). These
results also are in agreement with the observations made in the time–killing study. In
P. aeruginosa (Figure 7, lower panel), G2OLO-L2OL2 abolished growth only at the MIC,
and caused a 10 h delay in growth at 1/2 MIC and about a 2 h delay at 1/4 MIC. These
findings thus reveal a concentration-dependent effect. A similar effect was observed for
G2KLK-L2KL2, but this compound showed less capacity to delay growth when the bacteria
were exposed to 1/2 MIC and 1/4 MIC. When the bacteria were treated with G1OLO-L2OL2
at the MIC, a delay of approximately 6 h in growth was observed, while at 1/2 MIC or
1/4 MIC, there was no effect.
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Gram-positive and Gram-negative microorganisms. Thus, these SCPDs appear to be broad-
spectrum antibacterial compounds, except G1KLK-L2KL2, which was Gram-negative
selective. Nevertheless, further testing, i.e., time–kill kinetics and growth curves, revealed
considerable differences in the action, showing higher activity against Gram-negative
bacteria, especially E. coli. On the other hand, the cytotoxicity study in HepG2 and HEK293
cell lines showed higher toxicity for the higher branched peptides. Although some of the
compounds showed good antibacterial activity, the calculated TI make them unsuitable as
therapeutic agents. However, this was not the case for compound G1KLK-L2KL2, whose
TI makes it a strong lead candidate for the future development of an antibacterial agent
against Gram-negative bacteria.
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4. Materials and Methods
4.1. Chemical Synthesis
The SCPDs were synthesized manually by solid phase peptide synthesis methodology
using Fmoc/tBu strategy [19]. Briefly, Fmoc-Rink-amide-resin (0.76 mmol/g) was used
in combination with Fmoc-Leu-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Orn(Boc)-OH and Fmoc-
Lys(Boc)-OH for the units and Fmoc-Lys(Fmoc)-OH for the branching (5 equiv. for each
coupling). N,N′-diisopropylcarbodiimide (DIC) and OxymaPure (5 equiv. each) were used
as coupling reagents and N,N-dimethylformamide (DMF) as a solvent for a 30 min reaction.
Fmoc was removed by two treatments with piperidine-DMF (2:8) for 1 and 5 min. At
the end of the synthesis, the dendrimers were detached from the resin by treatment with
trifluoroacetic acid (TFA)-triisopropylsilane (TIS)-H2O (95:2.5:2.5) for 1 h. The filtrates were
collected in cold diethyl ether (DEE) and the precipitated was isolated by centrifugation and
decantation. The solid was washed three times with DEE, dissolved in 10% acetic acid and
lyophilized. All peptides were purified using C18 reverse phase high-performance liquid
chromatography (HPLC) and characterized by liquid chromatography-mass spectrometry
(LC-MS) (see SI).
4.2. Bacterial Strains, Media and Antimicrobial Substances
Nunclon Delta Surface sterile microtiter plates (including the Edge 2.0 plate) and
fetal calf serum were purchased from Thermo Fisher Scientific (Waltham, MA, USA).
Human serum from male AB plasma (sterile and filtered), antibiotics, antimycotic solution,
methylthiazol terazolium salt and all other reagents were obtained from Sigma (St. Louis,
MO, USA). All cell culture media and plasticware were procured from Whitehead Scientific
(Cape Town, South Africa).
Clinical isolates of CRE, MRSA and VRE were obtained from Lancet Laboratories,
Durban, South Africa, with approval BE394/15 from the Biomedical Research Ethical
Committee of the University of KwaZulu-Natal. Five reference strains of bacteria, namely
Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853, Enterococcus faecium ATCC
35667, Staphylococcus aureus ATCC 29213 and Bacillus subtilis ATCC 6051 were supplied by
the American Type Culture Collection (ATCC).
4.3. Determination of Minimum Inhibitory Concentrations
MIC values were determined by the broth microdilution method and the significance
of the values obtained was interpreted following the guidelines of the Clinical and Labora-
tory Standards for Antimicrobial Susceptibility Testing. [20]. The effect of human serum on
the antimicrobial effect of the molecules tested was determined in a similar way to the MIC
method used above in a solution of 50% human serum plus Mueller–Hinton broth.
4.4. Cytotoxicity
Cell viability was evaluated using the colorimetric MTT assay [21]. Human hepato-
carcinoma (HepG2) cells and human embryonic kidney 293 (HEK-293) cells used in the
drug toxicity assays were obtained from Cellonex (Johannesburg, South Africa). Viable
HepG2 and HEK293 cells (20,000 cells/well) were seeded into a 96-well microtiter plate
(200 µL) and allowed to attach overnight. The cells were exposed to varying concentra-
tions of the peptides for 24 h. After removal of the treatment medium, 20 µL of MTT
salt solution (5 mg/mL in 0.1M phosphate buffer saline (PBS)) and 100 µL of complete
cell culture medium (CCM) were added to each well. After a 4 h (37 ◦C) incubation,
the MTT salt solution was discarded and 100 µL of dimethyl sulphoxide (DMSO) were
added to each well (1 h, 37 ◦C). The optical density of the solubilized formazan product
was measured at 570 nm (reference λ of 690 nm) using a Bio-tek µQuant spectropho-
tometer (Winooski, VT, USA). The results were reported as percentage of cell viability
(
(
Absorbance o f treated cells
Absorbance o f control cells
)
× 100) versus log concentration of the extract. GraphPad Prism
(V5) (La Jolla, CA, USA) was used to obtain the half maximum inhibitory concentration
(IC50) for each compound.
Antibiotics 2021, 10, 695 12 of 13
4.5. Time–Kill Curves
Killing curve assays were performed with a starting inoculum of 6 × 106 CFU/mL.
Strains were tested against the peptides at concentrations below the MICs. Antimicrobials
were added to 5 mL of bacteria in the exponential phase of growth and incubated at 37 ◦C
with shaking. Samples were obtained aseptically at 0, 1, 2, 4, 6 and 24 h, diluted in Ringer
1/4 and plated on TSA for colony counting. The response of microbial strains to a single
antimicrobial was determined by lowering logarithms of viable bacteria. In accordance
with Lora-Tamayo et al. [22], an antimicrobial was considered active when a reduction of
≥1 log10 relative to the initial inoculum was observed.
4.6. Effect on Bacterial Growth Curves
The study of the growth dynamic of the S. aureus, E. coli and P.aeruginosa strains
against CAMPDs were assayed with a starting inoculum of 106–108 CFU/mL in a 10 mL
specific falcon tube. The experiment was performed by a real-time reverse-spin bioreactor
RTS-1 (Biosan SIA, Riga, Latvia) that applies non-invasive, mechanically driven rotation;
thus, the cell suspension is mixed efficiently, mixing and oxygening the culture at 37 ◦C.
Cell growth kinetics were recorded non-invasively in real time from data obtained from a
near-infrared optical system, every 15 min.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/antibiotics10060695/s1. Figure S1. 24 h Time-kill curves against E. coli for G2RLR-L2RL2,
G2OLO-L2OL2, G1KLK-L2KL2, and G1OLO-L2OL2. Figure S2. HPLC chromatogras and Mass
Spectra of all compounds synthesized.
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